ORAI1 and neoplasm: Therefore, targeting a Ca2+ entry/release pathway tightly coupled to either eNOS (i.e., Orai1, [173]) or CSE (yet to be identified) has the potential to interfere with multiple pro-angiogenic pathways and, therefore, exert a more profound anti-tumor effect.